Valerio Therapeutics S.A. acquires Emglev Therapeutics to advance next-generation antibody-based therapeutics
Acquiring Company
Valerio Therapeutics S.A
Acquired Company
Emglev Therapeutics
ParisParisBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareDescription
Valerio Therapeutics S.A., a clinical-stage biotechnology company, has announced the acquisition of Emglev Therapeutics, a spinoff of Institut Curie. This acquisition reinforces Valerio's commitment to developing innovative DNA Decoy therapeutics and expanding its capability to focus on discovering single domain antibodies (sdAbs) as drug and radio conjugates, bispecific T-cell engagers, blocking and binding sdAbs, or CAR-T sdAb drug candidates for multiple therapeutic areas.
Quick answer
Valerio Therapeutics S.A is acquiring Emglev Therapeutics, announced September 30, 2024. Valerio Therapeutics S.A is based in Paris, Ile-de-France, France.
- How much did Valerio Therapeutics S.A pay for Emglev Therapeutics?
- The deal value was not disclosed.
- What does Valerio Therapeutics S.A do?
- Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) is a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics.
- Where are Valerio Therapeutics S.A and Emglev Therapeutics based?
- Valerio Therapeutics S.A is based in Paris, Ile-de-France, France. Emglev Therapeutics is based in Paris, Ile-de-France, France.
- Who are the decision-makers at Valerio Therapeutics S.A?
- Fundz holds 5 contacts at Valerio Therapeutics S.A. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Flashpoint Therapeutics announces $50M Partnership with KAIMRC and Clinical Pipeline Expansion (November 14, 2024)
- Organon successfully acquires Dermavant Sciences Ltd. to expand dermatology portfolio (October 28, 2024)
- Merck completes acquisition of investigational B-Cell depletion therapy, CN201, from Curon Biopharmaceutical (October 1, 2024)
- Breeze Holdings Acquisition Corp. to merge with YD Biopharma Limited to revolutionize cancer prevention diagnostics (September 25, 2024)
- Organon acquires Dermavant Sciences to obtain the groundbreaking skin treatment VTAMA® (tapinarof) cream 1% (September 19, 2024)
- Organon to Acquire Dermavant Sciences Ltd. with Focus on Innovative Dermatologic Therapy VTAMA® (tapinarof) Cream, 1% (September 18, 2024)
Who to call at Valerio Therapeutics S.A, and when
When Valerio Therapeutics S.A changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Valerio Therapeutics S.A raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Valerio Therapeutics S.A, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Valerio Therapeutics S.A. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Valerio Therapeutics S.A makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Emglev Therapeutics?
Emglev Therapeutics was acquired by Valerio Therapeutics S.A, based in Paris. The deal was reported on September 30, 2024. Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) is a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics. Valerio Therapeutics S.A is privately held and operates in Biotechnology.
When did Valerio Therapeutics S.A acquire Emglev Therapeutics?
Valerio Therapeutics S.A's acquisition of Emglev Therapeutics was reported on September 30, 2024. Valerio Therapeutics S.A., a clinical-stage biotechnology company, has announced the acquisition of Emglev Therapeutics, a spinoff of Institut Curie. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Emglev Therapeutics do?
Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology. It is privately held, operating in Biotechnology, and is based in Paris.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.